Skip to main content

Danyelza Side Effects

Generic name: naxitamab

Medically reviewed by Last updated on Jan 13, 2024.

Note: This document contains side effect information about naxitamab. Some dosage forms listed on this page may not apply to the brand name Danyelza.

Applies to naxitamab: intravenous solution.


Intravenous route (Solution)

Warning: Serious Infusion-related Reactions and NeurotoxicitySerious Infusion-related Reactions: Naxitamab-gqgk can cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor. Premedicate prior to each naxitamab-gqgk infusion as recommended. Reduce the rate, interrupt infusion, or permanently discontinue naxitamab-gqgk based on severity.Neurotoxicity: Naxitamab-gqgk can cause severe neurotoxicity, including severe neuropathic pain, transverse myelitis, and reversible posterior leukoencephalopathy syndrome (RPLS). Premedicate to treat neuropathic pain as recommended. Permanently discontinue naxitamab-gqgk based on the adverse reaction and severity.

Serious side effects of Danyelza

Along with its needed effects, naxitamab (the active ingredient contained in Danyelza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking naxitamab:

More common

Less common

Other side effects of Danyelza

Some side effects of naxitamab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to naxitamab: intravenous solution.


Very common (10% or more): Lymphocytes decreased (74%), platelet count decreased (65%), neutrophils decreased (61%), hemoglobin decreased (48%)[Ref]


Very common (10% or more): Anaphylactic reaction (12%)[Ref]


Very common (10% or more): Influenza (12%)[Ref]


Very common (10% or more): Infusion related reactions (e.g., hypotension, bronchospasm, flushing, wheezing, stridor, urticaria, dyspnea, pyrexia, infusion-related reaction, face edema, edema mouth, tongue edema, lip edema, respiratory tract edema, chills, hypoxia, pruritus, rash) (all Grades: 100%; Grade 3 or 4: 68%)[Ref]


Very common (10% or more): Neurological disorders of the eye (e.g., unequal pupils, blurred vision, mydriasis) (24%)[Ref]


Very common (10% or more): Anorexia (53%), weight loss (12%)[Ref]


Very common (10% or more): Anxiety (26%), irritability (25%)[Ref]


Very common (10% or more): Cough (60%), cough (57%), rhinorrhea (24%), breath sounds abnormal (15%), rhinovirus infection (12%), enterovirus infection (13%), upper respiratory tract infection (12%)[Ref]


Very common (10% or more): Pain (e.g., pain, abdominal pain, pain in extremity, bone pain, neck pain, back pain, musculoskeletal pain) (all Grades: 100%; Grade 3 or 4: 72%), fatigue/asthenia (28%), pyrexia not occurring on the day of infusion or the day following an infusion (28%), contusion (15%)[Ref]


The most common adverse reactions were infusion-related reaction, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability. The most common Grade 3 or 4 laboratory abnormalities (5% or greater) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium, and decreased phosphate.[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (e.g., peripheral sensory neuropathy, paresthesia, neuralgia) (32%), headache (28%), depressed level of consciousness (24%), lethargy (14%)

Postmarketing reports: Transverse myelitis[Ref]


Very common (10% or more): Tachycardia/sinus tachycardia (84%), hypertension (all Grades: 44%; Grade 3 or 4: 4%), localized edema (25%)

Common (1% to 10%): Peripheral edema[Ref]


Very common (10% or more): Erythema multiforme (33%), urticaria not occurring on the day of infusion or the day following an infusion (32%), hyperhidrosis (17%), erythema (11%)[Ref]


Very common (10% or more): Vomiting (all Grades: 60%; Grade 3 or 4: 4%), diarrhea (all Grades: 56%; Grade 3 or 4: 8%), nausea (56%), constipation (15%), oropharyngeal pain (15%)[Ref]


1. Product Information. Danyelza (naxitamab). Y-mAbs Therapeutics. 2020.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.